Orano Med wins the "Innovation of the Year" award at the Grand Dîner de L'Usine Nouvelle

Orano Med, a subsidiary of the Orano group specialized in nuclear medicine, won the "Innovation of the Year" ("l’Innovation de l’année") award at the Grand Dîner de L'Usine Nouvelle for leaders of French industry held in Paris on Tuesday October 7.

Orano Med is a biotech company which is developing a new generation of targeted therapies against cancer using the unique properties of lead-212, a radioactive element with a very potent therapeutic payload. This “Targeted Alpha Therapy” approach opens new avenues for patients with cancer and limited options for treatment.

Targeted Alpha Therapy relies on a simple concept: combining the ability of biological molecules to target cancer cells with the cell-killing capabilities of alpha-emitting radioisotopes, while limiting the impact on surrounding healthy cells.

Orano Med's ambition is to develop and commercialize these innovative therapies. To achieve this, its teams have to master every step of a complex process: from preclinical research and clinical development through to the production and distribution of Targeted Alpha Therapies worldwide.

Guillaume Dureau, Senior Executive Vice President of the Projects Business Unit – Director of Innovation, R&D and New Activities said: "This award marks the culmination of 15 years of continuous work on innovation and collective commitment. I am proud to contribute to this unique venture! Orano Med is born of a strong ambition of the group: to recover nuclear materials for use in the health sector. Since then, we have taken some major steps forward – with the development of a robust pipeline lead-212-based drugs, the signature of an out-licensing agreement for AlphaMedixTM, the entry of Sanofi into our capital, and the development of our industrial platform to enable us to meet the expectations of patients worldwide."

Arnaud Lesegretain, President and CEO of Orano Med added "It is an honor to receive this Innovation of the Year award, on behalf of the whole team at Orano Med and in the company of its founder Patrick Bourdet. This award is recognition of the unfailing commitment of the Orano group and our employees since Orano Med's creation in 2009. Since then, we have been bold in our commitment to the path of progress in medical research and the fight against cancer. Orano Med is now imposing itself as a pioneer and leader in the sector worldwide, developing a new generation of targeted therapies for patients not responding to existing treatments."